People with restless legs syndrome may face a higher risk of Parkinson’s disease, but standard dopamine-based treatment could partly offset that danger, according to a large Korean study in JAMA Network Open from Korea University College of Medicine.
Drawing on national health insurance data and modern causal analysis methods, the team found that 1.6 percent of patients with restless legs syndrome developed Parkinson’s over 15 years, compared with 1.0 percent of similar adults without the condition, while those treated consistently with dopamine agonists showed only 0.5 percent incidence and a later onset of Parkinson’s. The findings suggest that restless legs syndrome might serve as an early clinical warning sign in some people and that timely treatment could help shape long-term brain health.
Restless legs syndrome, or RLS, is a common neurological sleep disorder in which people feel an irresistible urge to move their legs, typically worse at night and eased by movement. Parkinson’s disease is a progressive neurodegenerative condition best known for tremor, stiffness, and slowed movement, and both disorders have long been linked to changes in the brain’s dopamine system. Clinicians have suspected a connection between the two, but earlier studies were often limited to specific subgroups, such as mainly male cohorts, and left key questions about causality and treatment unanswered. Groups like the Restless Legs Syndrome Foundation offer education and support for people living with RLS and their families.
Big Data Study From Korea
To tackle those gaps, researchers led by neurologist Jong Hun Kim at Korea University Ansan Hospital analyzed records from the Korean National Health Insurance Service Sample Cohort, which tracks about one million people and is designed to mirror the broader population. The team identified 9,919 adults with restless legs syndrome using diagnostic codes and matched them one-to-one with 9,919 controls of the same age, sex, income level, region, and overall health burden. Participants were followed for up to 15 years, with statistical analyses performed between late 2024 and early 2025.
Over a median follow-up of 15 years, 158 people in the restless legs group (1.6 percent) were diagnosed with Parkinson’s disease, versus 99 in the control group (1.0 percent), corresponding to higher incidence rates per 10,000 person-years in the restless legs group. The researchers used a method called restricted mean survival time, which sidesteps some of the assumptions behind more common hazard ratios, and found that restless legs syndrome was associated with an earlier Parkinson’s diagnosis by about 0.05 years on average at the 15-year horizon, a small numerical difference but one that aligns with the higher overall incidence. The work builds on prior studies in veterans and male health professionals by extending the findings to a mixed-gender national cohort and layering in treatment status as a key modifier.
“One of the interpretations is that restless legs syndrome may serve as an early clinical marker for Parkinson’s disease, particularly among untreated individuals,” Prof. Kim said.
The team then split the restless legs cohort into two groups based on dopamine agonist therapy, drugs such as pramipexole or ropinirole that are first-line treatments for RLS symptoms. Patients who received dopamine agonists during at least two separate visits were classified as treated (3,077 people), while the remaining 6,842 were considered untreated or minimally treated. This distinction was designed to roughly separate primary restless legs cases that respond well to dopamine-targeting drugs from secondary cases linked to other medical problems.
Dopamine Therapy And Possible Protection
The contrast between the two restless legs subgroups was striking: Parkinson’s developed in 2.1 percent of the untreated group but in just 0.5 percent of those on dopamine agonists, with the treated group actually showing a slightly delayed time to Parkinson’s diagnosis compared with controls. In restricted mean survival time analyses at 15 years, the untreated restless legs group reached Parkinson’s diagnosis about 0.09 years earlier than controls, while the treated group reached it about 0.03 years later, and both differences were statistically significant. These patterns hint that adequate dopamine-agonist therapy might either offer some neuroprotective benefit or help clinicians more accurately distinguish true restless legs syndrome from early Parkinson’s masquerading as sleep symptoms.
The authors caution that the dopamine story probably isn’t the whole explanation. They point to other biological pathways that might link restless legs and Parkinson’s, including chronic sleep disruption, iron deficiency, and changes in immune or metabolic signaling, all of which have been implicated in neurodegeneration by previous work. Untreated restless legs can severely fragment sleep, and poor sleep has been tied to impaired clearance of waste proteins like alpha-synuclein from the brain, potentially contributing to Parkinson’s pathology.
“Monitoring and treating RLS may not only improve sleep quality but could also influence long-term neurological health,” Prof. Kim said.
Despite the size and sophistication of the analysis, the study has limits: diagnoses were based on insurance codes rather than detailed clinical exams, and observational data can’t prove that restless legs or its treatment directly cause or prevent Parkinson’s. Some individuals with early Parkinson’s may initially have been labeled as having restless legs, and dividing patients by treatment exposure can’t fully separate different biological subtypes of the syndrome. Still, the findings suggest that clinicians should take restless legs syndrome seriously not just as a sleep complaint but as a possible early warning sign in a subset of patients and that dopamine-based therapy may offer more than just symptom relief.
For people living with restless legs, the results don’t mean that Parkinson’s is inevitable, but they do underscore the value of medical evaluation, targeted treatment, and close follow-up over time. Alongside specialist care, organizations such as the Parkinson’s Foundation provide information, support programs, and community resources for those navigating Parkinson’s disease. Future work using even larger national databases and more detailed clinical phenotyping may help pinpoint which patients with restless legs are most at risk and which treatment strategies best protect brain health in the long run.
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.
I’ve been doing the ALS/MND treatment from limitless health center . I was diagnosed with bulbar ALS in June 2024. I received the ALS/MND treatment for my ALS approximately four months ago; since then, i have stopped using a feeding tube, speech is getting better by the day, sleeps well, works out frequently. I’m surprised a lot of PALs, and their CALs haven’t heard of it.